Rina Maria Zureikat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rina Maria Zureikat has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Matthew Roman Kaczynski
Student Research Club at the 1st Clinic of Psychiatry, Psychotherapy, and Early Intervention, Department of Psychiatry, Medical University of Lublin, Głuska 1, 20-439 Lublin, Poland
2 shared publications - Michael Mieczyslaw Kaczynski
Student Research Club at the 1st Clinic of Psychiatry, Psychotherapy, and Early Intervention, Department of Psychiatry, Medical University of Lublin, Głuska 1, 20-439 Lublin, Poland
2 shared publications - Alicja Forma
Department of Correct, Clinical and Imaging Anatomy, Medical University of Lublin, ul. Jaczewskiego 4, 20-090 Lublin, Poland
1 shared publication - Hanna Karakuła-Juchnowicz
1st Department of Psychiatry, Psychotherapy and Early Intervention, Medical University of Lublin, Gluska Street 1, 20-439 Lublin, Poland
1 shared publication - Jacek Baj
Department of Correct, Clinical, and Imaging Anatomy, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland
1 shared publication - James Curtis Dring
Chair and Department of Forensic Medicine, Medical University of Lublin, ul. Jaczewskiego 8B, 20-090 Lublin, Poland
1 shared publication
Latest Publications
- Open Access
- 31 August 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (9) , 1957
Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework
Antipsychotic-associated metabolic dysfunction contributes substantially to cardiometabolic morbidity and premature mortality in schizophrenia spectrum disorders, with the greatest burden among patients treated with clozapine and olanzapine. This review focuses on patients with schizophrenia spectrum disorders receiving these two agents, in whom the relevant psychiatric evidence is concentrated. Existing pharmacological interventions, including metformin and glucagon-like peptide-1 receptor agonists (GLP-1RAs), produce clinically meaningful but often incomplete benefits. Retatrutide (LY3437943) is a once-weekly triple agonist of the GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors that produced a mean body-weight reduction of 24.2% at 48 weeks under the efficacy estimand in a Phase 2 obesity trial; company-reported Phase 3 results from four trials, not yet peer-reviewed, describe reductions of up to 28.7%. This narrative review examines the rationale for investigating retatrutide in this setting, drawing on retatrutide trials in non-psychiatric populations, the pathophysiology of antipsychotic-induced weight gain, and emerging evidence for incretin-based therapies in antipsychotic-treated populations. The glucagon component is of particular mechanistic interest because it increases basal energy expenditure, a pathway not engaged by mono- or dual agonists; whether this could partially compensate for the reduced physical activity associated with antipsychotic-related sedation is untested and is presented here solely as a hypothesis. Indirect support comes from randomized trials and meta-analyses of GLP-1RAs in clozapine- or olanzapine-treated patients, which report reductions in body weight and glycemic impairment without evidence of worsening psychotic symptoms. No trial has evaluated retatrutide in an antipsychotic-treated population. Future studies should therefore characterize gastrointestinal tolerability, potential interaction with clozapine-associated gastrointestinal hypomotility, possible effects on clozapine and olanzapine exposure, adherence and feasibility, and the dysesthesia observed in retatrutide trials, which was dose-related in most but not all trials. Dedicated randomized controlled trials are needed to determine the efficacy and safety of retatrutide in patients with schizophrenia spectrum disorders receiving clozapine or olanzapine.
- 31 August 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (9) , 1957
Open AccessPotential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework
Antipsychotic-associated metabolic dysfunction contributes substantially to cardiometabolic morbidity and premature mortality in schizophrenia spectrum disorders, with the greatest burden among patients treated with clozapine and olanzapine. This review focuses on patients with schizophrenia spectrum disorders receiving these two agents, in whom the relevant psychiatric evidence is concentrated. Existing pharmacological interventions, including metformin and glucagon-like peptide-1 receptor agonists (GLP-1RAs), produce clinically meaningful but often incomplete benefits. Retatrutide (LY3437943) is a once-weekly triple agonist of the GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors that produced a mean body-weight reduction of 24.2% at 48 weeks under the efficacy estimand in a Phase 2 obesity trial; company-reported Phase 3 results from four trials, not yet peer-reviewed, describe reductions of up to 28.7%. This narrative review examines the rationale for investigating retatrutide in this setting, drawing on retatrutide trials in non-psychiatric populations, the pathophysiology of antipsychotic-induced weight gain, and emerging evidence for incretin-based therapies in antipsychotic-treated populations. The glucagon component is of particular mechanistic interest because it increases basal energy expenditure, a pathway not engaged by mono- or dual agonists; whether this could partially compensate for the reduced physical activity associated with antipsychotic-related sedation is untested and is presented here solely as a hypothesis. Indirect support comes from randomized trials and meta-analyses of GLP-1RAs in clozapine- or olanzapine-treated patients, which report reductions in body weight and glycemic impairment without evidence of worsening psychotic symptoms. No trial has evaluated retatrutide in an antipsychotic-treated population. Future studies should therefore characterize gastrointestinal tolerability, potential interaction with clozapine-associated gastrointestinal hypomotility, possible effects on clozapine and olanzapine exposure, adherence and feasibility, and the dysesthesia observed in retatrutide trials, which was dose-related in most but not all trials. Dedicated randomized controlled trials are needed to determine the efficacy and safety of retatrutide in patients with schizophrenia spectrum disorders receiving clozapine or olanzapine.
- Open Access
- 16 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6821
Review of Applications of Zeolites in Dermatology: Molecular Perspectives and Translational Potentials
Zeolites, microporous aluminosilicates with tuneable physicochemical properties, have garnered increasing attention in dermatology due to their antimicrobial, detoxifying, and drug delivery capabilities. This review evaluates the structural characteristics, therapeutic mechanisms, and clinical applications of zeolites—including clinoptilolite, ZSM-5, ZIF-8, and silver/zinc-functionalized forms—across skin infections, wound healing, acne management, and cosmetic dermatology. Zeolites demonstrated broad-spectrum antibacterial and antifungal efficacy, enhanced antioxidant activity, and biocompatible drug delivery in various dermatological models. Formulations such as silver–sulfadiazine–zeolite composites, Zn–clinoptilolite for acne, and zeolite-integrated microneedles offer innovative avenues for targeted therapy. Zeolite-based systems represent a promising shift toward multifunctional, localized dermatologic treatments. However, further research into long-term safety, formulation optimization, and clinical validation is essential to transition these materials into mainstream therapeutic use.
- 16 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6821
Open AccessReview of Applications of Zeolites in Dermatology: Molecular Perspectives and Translational Potentials
Zeolites, microporous aluminosilicates with tuneable physicochemical properties, have garnered increasing attention in dermatology due to their antimicrobial, detoxifying, and drug delivery capabilities. This review evaluates the structural characteristics, therapeutic mechanisms, and clinical applications of zeolites—including clinoptilolite, ZSM-5, ZIF-8, and silver/zinc-functionalized forms—across skin infections, wound healing, acne management, and cosmetic dermatology. Zeolites demonstrated broad-spectrum antibacterial and antifungal efficacy, enhanced antioxidant activity, and biocompatible drug delivery in various dermatological models. Formulations such as silver–sulfadiazine–zeolite composites, Zn–clinoptilolite for acne, and zeolite-integrated microneedles offer innovative avenues for targeted therapy. Zeolite-based systems represent a promising shift toward multifunctional, localized dermatologic treatments. However, further research into long-term safety, formulation optimization, and clinical validation is essential to transition these materials into mainstream therapeutic use.